Depressive Disorder, Treatment-Resistant Clinical Trials

57 clinical trials for Depressive Disorder, Treatment-Resistant across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response — RECRUITING · PHASE2
• A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression — RECRUITING · PHASE3
• Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression — RECRUITING · PHASE2
• NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits — RECRUITING · PHASE1
• rTMS With and Without Text4Support for the Treatment of Resistant Depression. — RECRUITING · NA
• Accelerated vs. Conventional Theta Burst Stimulation for Late-life Depression — RECRUITING · NA
• Effects of a Classic High-frequency rTMS Treatment Versus a Deep rTMS Treatment — RECRUITING · NA
• Intravenous Ketamine for Treatment-Resistant Depression — RECRUITING · PHASE2
• OSU6162 as add-on in SSRI/SNRI-resistant Depression — RECRUITING · PHASE2
• One-Day cTBS Over the Precuneus — NOT_YET_RECRUITING · NA
• Dopaminergic Dysfunction in Late-Life Depression — COMPLETED · PHASE2
• Improving Brain Stimulation Through Imaging — COMPLETED
• A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression — COMPLETED · PHASE4
• Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment — COMPLETED · PHASE2
• Adaptive tDCS for Treatment-Resistant MDD — TERMINATED · PHASE1
• NESBID: Neuro-Stimulation of the Brain in Depression — WITHDRAWN · NA
• Behavioural Activation Therapy and Esketamine for Resistant Depression — TERMINATED · NA
• Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression — COMPLETED · NA
• Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD) — OTHER
• Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression. — COMPLETED · PHASE1
• A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression — COMPLETED · PHASE3
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression — COMPLETED · PHASE3
• A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression — COMPLETED · PHASE3
• A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression — COMPLETED · PHASE3
• Treatment-Resistant Depression Cohort in Europe — COMPLETED
• Treatment Resistant Depression in America Latina — COMPLETED
• A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression — WITHDRAWN · PHASE3
• An Epidemiology Study of Treatment Resistant Depression in the United States (US) — COMPLETED
• A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression — COMPLETED · PHASE4
• Psilocybin-assisted Interpersonal Therapy for Depression — COMPLETED · NA
• Long Term Follow-up of Deep Brain Stimulation for Treatment-Resistant Depression — TERMINATED · NA
• Synaptic Imaging and Network Activity in Treatment Resistant Depression — COMPLETED · NA
• Epidemiology of Treatment Resistant Depression in Taiwan — COMPLETED
• Accelerated Bilateral Sequential Theta Burst Stimulation in Older Adults With Treatment-resistant Depression — OTHER · NA
• Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD — COMPLETED · PHASE2
• Chronic Anergic-anhedonic Depression Open Trial — OTHER
• Treatment Resistant Depression (Pilot) — COMPLETED · NA
• IMPase in Treatment-resistant Depression — OTHER · PHASE1
• In Vitro Modeling of Drug-resistant Psychiatric Disorders Using Induced Pluripotent Cells — OTHER
• Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine — COMPLETED · PHASE1
• Neuromodulation in the Elderly Depressed: a Brain Imaging Pilot Study — OTHER · NA
• Music as an Intervention to Improve Hemodynamic Tolerability of Ketamine in Depression — COMPLETED · NA
• rTMS With and Without iCBT For the Treatment of Resistant Depression (TRD) — COMPLETED · NA
• Treatment for Major Depressive Disorder With Intermittent Theta-burst Stimulation — OTHER · NA
• Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies — COMPLETED · PHASE2
• Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression — COMPLETED · PHASE2
• Sevoflurane for Treatment-Resistant Depression — OTHER · NA
• Lithium Versus Quetiapine in Treatment Resistant Depression — OTHER · PHASE4
• Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine — COMPLETED · PHASE2
• Healthy Lifestyle Promotion as Adjunctive Teletherapy for Treatment-resistant Major Depression — OTHER · NA

Refine this search